Eli Lilly and Company

Michael James Genin

Alan M Warshawsky

Michael Gregory Bell

Tianwei Ma

Ryan Edward Stites

Peter Ambrose Lander

Lindsay Stelzer

Peter Rudolph Manninen

Robert Anthony Doti

Jason Matthew Ochoada

Qing Shi

Ana Belen Bueno Melendo

Francisco Javier Agejas-Chicharro

William Glen Holloway

Cynthia Darshini Jesudason

Nathan Bryan Mantlo

Richard Duane Johnston

Quanrong Shen

Fucheng Qu

John Richard Morphy

Matthew Scott Dowling

Lindsay Scott Stelzer

The present invention provides a compound of Formula I: wherein X is CHCH, CHCHCH, OCH, or CHO; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CHCH, then R is other than cyclopropyl; for use as a human PDE inhibitor. 

[1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes

The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor. 

[1,2,4]Triazolo[4,3-A]pyrazin-6(5H)-one derivatives

Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia. 

Compounds and methods for modulating FXR

Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. 

Compounds of formula and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. 

Compounds and methods for modulating FX-receptors

Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. 

FXR agonists

Growing community of inventors

Zionsville, IN, United States of America

Michael James Genin